Sarepta Therapeutics’ (NASDAQ:SRPT) “Outperform” Rating Reaffirmed at UBS Group

UBS Group reiterated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Wednesday, December 27th, 247wallst.com reports. UBS Group currently has a $56.51 price target on the biotechnology company’s stock, down from their previous price target of $76.00.

SRPT has been the topic of a number of other research reports. Credit Suisse Group reaffirmed an outperform rating and issued a $81.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Robert W. Baird reaffirmed a buy rating and issued a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. William Blair reaffirmed an outperform rating on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Piper Jaffray Companies reaffirmed an overweight rating and issued a $55.00 price objective (up previously from $50.00) on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. Finally, JPMorgan Chase & Co. reaffirmed a hold rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $63.88.

Shares of Sarepta Therapeutics (SRPT) opened at $58.99 on Wednesday. The stock has a market capitalization of $3,810.00, a P/E ratio of -28.92 and a beta of 1.37. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $60.22. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The company had revenue of $45.95 million for the quarter, compared to the consensus estimate of $41.29 million. During the same quarter last year, the company earned ($0.95) EPS. equities analysts forecast that Sarepta Therapeutics will post -3.07 earnings per share for the current fiscal year.

In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Douglas S. Ingram bought 38,138 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the acquisition, the chief executive officer now owns 420,196 shares in the company, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. 9.60% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. boosted its holdings in Sarepta Therapeutics by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 271 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 2,474 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Sarepta Therapeutics by 140.9% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 2,493 shares during the period. Fox Run Management L.L.C. purchased a new position in Sarepta Therapeutics during the 3rd quarter valued at $204,000. Finally, Bayesian Capital Management LP purchased a new position in Sarepta Therapeutics during the 2nd quarter valued at $206,000. Institutional investors own 82.02% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Sarepta Therapeutics’ (NASDAQ:SRPT) “Outperform” Rating Reaffirmed at UBS Group” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://stocknewstimes.com/2018/01/12/sarepta-therapeutics-srpt-outperform-rating-reaffirmed-at-ubs-group-4.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply